Administrative Core

行政核心

基本信息

项目摘要

Administrative Core Summary An efficient administrative structure is essential to the design and implementation of the TUCAIN U54 Center. The Admin Core will be focused on facilitating communication, collaboration, planning, data sharing, and scientific and financial oversight of the Shared Resource Cores and Research Projects within TUCAIN. Through the Admin Core, we will oversee all the goals of the Center and ensure their successful, cost-effect, and timely completion. The Admin Core will coordinate, schedule, and implement monthly internal teleconferencing meetings among the Center participants, and will assist the PIs of the Cores and Projects in the preparation of progress reports, internal compliance filings, and manuscripts to support the overall goals of TUCAIN. The Admin Core will be responsible for the following Specific Aims: (1) Create an administrative, communication and leadership structure for TUCAIN. (2) Provide an effective and responsive line of communication between TUCAIN members, the NIH, and other members of SeroNet. (3) Ensure the full integration of Projects and Cores within TUCAIN. (4) Assist Core and Project PIs with administrative aspects. (5) Communicate with other members of SeroNet to facilitate collaboration and coordination. (6) Provide each Core and Project under TUCAIN with robust, integrated data management and statistical support. (7) Coordinate periodic evaluation of TUCAN and engage the Steering Committee to ensure the program is successful in its overarching goal of understanding immune responses to SARS-CoV-2.
行政核心概述

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Scribner Schieffelin其他文献

John Scribner Schieffelin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Scribner Schieffelin', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10688384
  • 财政年份:
    2020
  • 资助金额:
    $ 47.29万
  • 项目类别:
IDENTIFICATION OF PROTECTIVE / PATHOGENIC HUMAN B CELL EPITOPES IN DENGUE VIRUS
登革热病毒中保护性/致病性人类 B 细胞表位的鉴定
  • 批准号:
    8360452
  • 财政年份:
    2011
  • 资助金额:
    $ 47.29万
  • 项目类别:
Project 2. Expansion of Clinical Research Capacity at Kenema Government Hospital
项目 2. 凯内马政府医院临床研究能力扩展
  • 批准号:
    9223661
  • 财政年份:
  • 资助金额:
    $ 47.29万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 47.29万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 47.29万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 47.29万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.29万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 47.29万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 47.29万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 47.29万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 47.29万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 47.29万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 47.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了